[Mechanism research in somatostatin reverting the chemosensitivity of GBC-SD cell line].
OBJECTIVE
To investigate the mechanism of increasing chemosensitivity of gallbladder carcinoma stimulated by somatostatin.


METHODS
GBC-SD cells were divided into four groups: SST-alone-treated group, Doxorubicin (DOX)-alone-treated group and co-treated group (co-treatment of SST and DOX). In the control group, the cells were cultivated by medium only. In SST-alone-treated group, the cells were cultivated by medium with SST in the concentration of 75 microg/ml. In DOX-alone-treated group, the cells were cultivated by medium with DOX in the gradient concentrations of 5, 10, 20 microg/ml. In the co-treated group, cells were first cultivated by medium with 75 microg/ml SST for 24 h, followed by the addition of DOX in the gradient concentrations mentioned above. Cell viability curve was measured by MTT assay at 24, 48, 72 and 96 h, respectively. Meanwhile, the alterations of protein expressions of ICBP90 and Topo IIalpha after treatment of SST were examined by Western blot.


RESULTS
The treatment of SST alone on GBC-SD cells did not exert significantly inhibitory effect compared to the control group (P > 0.05). However, 24 h after the treatment of SST, the protein expressions of ICBP90 and Topo IIalpha were both up-regulated (P < 0.05).


CONCLUSIONS
Up-regulated the expression of ICBP90 by somatostatin maybe the cause of overexpression of Topo IIalpha, which leads to the enhanced lethal effect of DOX.
Qin
Yi-yu
YY
Department of General Surgery, Xin Hua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200092, China.
Li
Ji-yu
JY
Li
Song-gang
SG
Yue
Jia-ning
JN
Quan
Zhi-wei
ZW
D000951:Antigens, Neoplasm / Q000378:metabolism; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000378:metabolism; D004317:Doxorubicin / Q000494:pharmacology; D004347:Drug Interactions; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005706:Gallbladder Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D006801:Humans; D013004:Somatostatin / Q000494:pharmacology*
D000951:Antigens, Neoplasm; D004268:DNA-Binding Proteins; D013004:Somatostatin; D004317:Doxorubicin; D004250:DNA Topoisomerases, Type II